LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Emergent BioSolutions Inc

Slēgts

SektorsVeselības aprūpe

6.34 -1.86

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.28

Max

6.35

Galvenie mērījumi

By Trading Economics

Ienākumi

99M

68M

Pārdošana

33M

222M

EPS

0.71

Peļņas marža

30.603

Darbinieki

900

EBITDA

120M

133M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+108.98% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

30M

347M

Iepriekšējā atvēršanas cena

8.2

Iepriekšējā slēgšanas cena

6.34

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. maijs 10:30 UTC

Top Ziņas

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

2025. g. 31. maijs 06:30 UTC

Peļņas

5 Things We've Learned From Retail Earnings -- Barrons.com

2025. g. 31. maijs 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 23:51 UTC

Iegādes, apvienošanās, pārņemšana

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

2025. g. 30. maijs 21:30 UTC

Top Ziņas

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

2025. g. 30. maijs 21:15 UTC

Top Ziņas

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

2025. g. 30. maijs 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 30. maijs 20:44 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

2025. g. 30. maijs 20:24 UTC

Top Ziņas

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

2025. g. 30. maijs 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 19:44 UTC

Tirgus saruna

Gold Breaks 4-Month Winning Streak -- Market Talk

2025. g. 30. maijs 19:38 UTC

Tirgus saruna

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

2025. g. 30. maijs 19:29 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

2025. g. 30. maijs 19:14 UTC

Tirgus saruna

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

2025. g. 30. maijs 19:05 UTC

Tirgus saruna

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

2025. g. 30. maijs 18:51 UTC

Tirgus saruna

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

2025. g. 30. maijs 18:37 UTC

Tirgus saruna
Peļņas

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

2025. g. 30. maijs 18:04 UTC

Top Ziņas

S&P 500 Falls After More Trump-China Friction -- WSJ

2025. g. 30. maijs 17:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 30. maijs 17:47 UTC

Tirgus saruna

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

2025. g. 30. maijs 17:40 UTC

Iegādes, apvienošanās, pārņemšana

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

2025. g. 30. maijs 17:38 UTC

Tirgus saruna

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

2025. g. 30. maijs 17:31 UTC

Tirgus saruna

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

2025. g. 30. maijs 17:14 UTC

Top Ziņas

American Consumers Are Still Gloomy on the Economy -- 3rd Update

2025. g. 30. maijs 16:31 UTC

Peļņas

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

2025. g. 30. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 30. maijs 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 30. maijs 16:16 UTC

Top Ziņas

S&P 500 Falls After Trump Hits Out at China -- WSJ

2025. g. 30. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 30. maijs 16:14 UTC

Top Ziņas

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

108.98% augšup

Prognoze 12 mēnešiem

Vidējais 13.5 USD  108.98%

Augstākais 15 USD

Zemākais 12 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

2

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.95 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.